resTORbio

resTORbio, Inc. was a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing novel therapeutics for aging-related diseases. The company focused on inhibiting the target of rapamycin complex 1 (TORC1), a pathway linked to the decline in various organ functions associated with aging. Its lead drug candidate, RTB101, is an oral, selective inhibitor of TORC1, which was undergoing Phase 1b/2a clinical trials for the treatment of Parkinson’s disease and neurodegenerative conditions. Additionally, resTORbio collaborated with TrialSpark to explore RTB101's potential for treating COVID-19. Founded in 2016, the company aimed to address a range of aging-related health issues, including cancer, heart disease, and diabetes. In September 2020, resTORbio was acquired by Adicet Bio, Inc. in a reverse merger transaction.